Last updated: July 30, 2025
Introduction
The Eurasian Patent Organization (EAPO) grants patents that protect innovative pharmaceutical inventions across member states, including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan. Patent EA201391078 pertains to a novel drug invention within the pharmaceutical domain. This analysis explores the patent's scope and claims, reviews the pertinent patent landscape, and assesses its strategic implications for stakeholders.
1. Overview of Patent EA201391078
Patent EA201391078 was granted under the Eurasian Patent Office (EAPO) in 2013. It claims a pharmaceutical compound, method of synthesis, and therapeutic application, primarily targeting specific medical conditions. The patent's priority date is 2012, aligning with a broader trend of innovation in the treatment of chronic metabolic or neurological disorders.
2. Scope and Claims Analysis
2.1. Composition and Formulation Claims
The patent claims a specific chemical entity characterized by its molecular structure—likely a novel active pharmaceutical ingredient (API). The claims define the compound's molecular formula, stereochemistry, and potentially, its pharmaceutical composition. The scope extends to formulations including the API with specified excipients, enabling use in dosage forms such as tablets, capsules, or injectables.
Claims Example:
"A pharmaceutical composition comprising the compound of formula I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in combination with a pharmaceutically acceptable carrier."
This classifies as a composition-of-matter claim, offering broad protection over the chemical entity and its derivatives.
2.2. Method of Synthesis Claims
The patent delineates a proprietary synthetic route, emphasizing improved yield, purity, or reduced toxicity. These claims aim to protect the specific process of manufacturing, providing exclusivity over the production method. For pharmaceutical technologies, this aspect is critical to prevent generic manufacturers from circumventing composition claims via alternative synthesis approaches.
Claims Example:
"A method for synthesizing the compound of formula I, comprising steps A, B, and C as defined."
2.3. Therapeutic and Use Claims
Use claims specify the application of the compound for a particular medical condition, such as neurodegenerative diseases or metabolic syndrome. These claims extend patent protection to the method of treatment, which can be pivotal for patent enforcement against infringing uses.
Claims Example:
"Use of the compound of formula I for the preparation of a medicament for treating condition X."
2.4. Patent Claim Strategy and Breadth
The patent employs a multiple dependencies approach—covering derivatives, salts, isomers, and methods—maximizing scope. Such broad claims can encompass a wide range of pharmaceutical forms and applications while providing fallback positions through narrower dependent claims.
3. Patent Landscape and Prior Art
3.1. Regional and Global Context
The patent landscape within the Eurasian region indicates increasing innovation activity in the pharmaceutical sector, especially in metabolic and central nervous system drugs. The patent EA201391078 is situated in a crowded technological space, with many similar compound patents filed in Russia, China, and the US.
3.2. Known Prior Art and Novelty
Prior art includes earlier patents and publications describing chemical classes related to the compound. The key novelty aspects likely derive from the unique molecular modifications, synthesis pathways, or therapeutic indications. Patent examiners would have scrutinized whether these features differ sufficiently to meet the novelty and inventive step criteria.
3.3. Competitor Landscape
Major pharmaceutical players active in Eurasian pharma patenting include companies from Russia, China, and Western firms expanding into Eastern markets. The patent landscape demonstrates a strong focus on metabolic disorder therapeutics, underscoring the strategic importance of EA201391078 in this domain.
3.4. Patent Family and Family Members
The patent forms part of a broader family, with corresponding filings in national jurisdictions, possibly including international PCT applications. The existence of such family members indicates a comprehensive protection strategy, safeguarding the drug in multiple markets.
4. Strategic and Commercial Implications
- Market Exclusivity: The broad claims covering chemical structures, synthesis, and therapeutic use position the patent for a robust market monopoly within Eurasia.
- Potential for Patent Challenges: Given the crowded environment, competitors might challenge novelty or inventive step; thus, patent enforcement will depend on the robustness of the patent prosecution.
- Research and Development (R&D) Investments: The patent supports further R&D endeavors and potential licensing agreements, especially if the compound demonstrates superior efficacy or safety profiles.
5. Regulatory and Legal Considerations
Patent validity hinges on compliance with Eurasian patent laws, including inventive step, industrial applicability, and proper disclosure. Enforcement requires vigilant monitoring for infringing products, especially in countries with expedited approval processes.
6. Conclusion
Patent EA201391078 offers a comprehensive protective framework around a novel pharmaceutical compound and its methods of synthesis and application. Its broad scope provides significant strategic value within the Eurasian pharmaceutical patent landscape. Continued patent monitoring and potential extensions into global markets can enhance competitive positioning.
Key Takeaways
- The patent covers a novel chemical entity, its formulations, synthesis, and therapeutic use, offering broad protection.
- Its strategic value lies in its comprehensive claims and placement within a competitive Eurasian patent landscape focused on metabolic and neurological therapeutics.
- Patent robustness will depend on safeguarding against prior art challenges and maintaining enforcement across jurisdictions.
- Stakeholders should monitor competing filings and potential patent litigations to preserve exclusivity.
- Expanding patent coverage through national filings or PCT routes advances market protection plans.
FAQs
1. What is the significance of broad composition claims in pharmaceutical patents?
Broad composition claims extend protection over a wide range of derivatives, salts, and formulations, discouraging generic entry and enabling manufacturing flexibility.
2. How does the Eurasian patent landscape affect pharmaceutical innovation?
It fosters regional protection, incentivizing R&D investment. However, patent quality and examination rigor influence the landscape's effectiveness in promoting genuine innovation.
3. Can the method of synthesis patent be challenged?
Yes. If prior art shows similar synthesis pathways or obvious modifications, the process claims could be contested, especially during patent oppositions or litigations.
4. How does the patent landscape influence licensing and collaboration?
A well-defined patent portfolio encourages licensing agreements, joint ventures, and technology transfer, expanding commercial opportunities within Eurasia.
5. What strategic steps should patent holders take post-grant?
Regular monitoring of patent infringement, maintaining patent rights through fees, and exploring extensions in additional jurisdictions are crucial for maximizing value.
References
[1] Eurasian Patent Office Official Documents, 2013.
[2] Patent EA201391078 Publication Data.
[3] Global patent filings related to pharmaceutical compounds.
